P
This clinical-stage biotechnology company utilizes machine learning to enhance the design and development of peptide therapeutics, focusing on precision engineering. Their lead candidate, PLG0206, is a broad-spectrum anti-infective currently in clinical trials for treating prosthetic joint infections, a condition with significant treatment challenges.
Updated 20 months ago
Funding
Funding not disclosed
CFFunding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- This clinical-stage biotechnology company utilizes machine learning to enhance the design and development of peptide therapeutics, focusing on precision engineering. Their lead candidate, PLG0206, is a broad-spectrum anti-infective currently in clinical trials for treating prosthetic joint infections, a condition with significant treatment challenges.